4.7 Review

Historical Lessons in Translational Medicine Cyclooxygenase Inhibition and P2Y12 Antagonism

期刊

CIRCULATION RESEARCH
卷 112, 期 1, 页码 174-194

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCRESAHA.111.300271

关键词

aspirin; platelet; prostaglandin

资金

  1. National Heart Lung and Blood Institute of the National Institutes of Health [HL062250, U54HL117798]

向作者/读者索取更多资源

The development of drugs that inhibit platelets has been driven by a combination of clinical insights, fundamental science, and sheer luck. The process has evolved as the days of stumbling on therapeutic gems, such as aspirin, have long passed and have been replaced by an arduous process in which a drug is designed to target a specific protein implicated in a well-characterized pathophysiological process, or so we would like to believe. The development of antiplatelet therapy illustrates the importance of understanding the mechanisms of disease and the pharmacology of the compounds we develop, coupled with careful clinical experimentation and observation and, yes, still, a fair bit of luck. (Circ Res. 2013; 112: 174-194.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据